vs

Side-by-side financial comparison of Monte Rosa Therapeutics, Inc. (GLUE) and FiscalNote Holdings, Inc. (NOTE). Click either name above to swap in a different company.

FiscalNote Holdings, Inc. is the larger business by last-quarter revenue ($22.2M vs $12.8M, roughly 1.7× Monte Rosa Therapeutics, Inc.). On growth, Monte Rosa Therapeutics, Inc. posted the faster year-over-year revenue change (38.5% vs -24.7%). Monte Rosa Therapeutics, Inc. produced more free cash flow last quarter ($99.8M vs $-1.9M).

Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted molecular glue degrader therapies. Its pipeline addresses unmet medical needs across oncology, rare genetic disorders and immunological diseases, with operations focused on advancing novel treatments for global patient populations.

FiscalNote Holdings, Inc., or commonly FiscalNote, is a publicly traded software, data, and media company headquartered in Washington, D.C. The company was founded by Timothy Hwang, Gerald Yao, and Jonathan Chen in 2013. FiscalNote provides software tools, platforms, data services, and news through the FiscalNote Government Relationship Management (GRM) service, its core product. The company also uses an artificial intelligence platform to analyze proposed U.S. legislation based on key phrase...

GLUE vs NOTE — Head-to-Head

Bigger by revenue
NOTE
NOTE
1.7× larger
NOTE
$22.2M
$12.8M
GLUE
Growing faster (revenue YoY)
GLUE
GLUE
+63.2% gap
GLUE
38.5%
-24.7%
NOTE
More free cash flow
GLUE
GLUE
$101.7M more FCF
GLUE
$99.8M
$-1.9M
NOTE

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GLUE
GLUE
NOTE
NOTE
Revenue
$12.8M
$22.2M
Net Profit
$-27.1M
Gross Margin
Operating Margin
-258.3%
-83.7%
Net Margin
-212.1%
Revenue YoY
38.5%
-24.7%
Net Profit YoY
-13.5%
EPS (diluted)
$-2.81

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GLUE
GLUE
NOTE
NOTE
Q4 25
$22.2M
Q3 25
$12.8M
$22.4M
Q2 25
$23.2M
$23.3M
Q1 25
$84.9M
$27.5M
Q4 24
$60.6M
$29.5M
Q3 24
$29.4M
Q2 24
$29.2M
Q1 24
$32.1M
Net Profit
GLUE
GLUE
NOTE
NOTE
Q4 25
Q3 25
$-27.1M
$-24.9M
Q2 25
$-12.3M
$-13.3M
Q1 25
$46.9M
$-4.3M
Q4 24
$13.4M
Q3 24
$-14.9M
Q2 24
$-12.8M
Q1 24
$50.6M
Operating Margin
GLUE
GLUE
NOTE
NOTE
Q4 25
-83.7%
Q3 25
-258.3%
-43.4%
Q2 25
-67.1%
-31.9%
Q1 25
51.9%
-50.0%
Q4 24
21.4%
-19.4%
Q3 24
-23.1%
Q2 24
-27.2%
Q1 24
-35.6%
Net Margin
GLUE
GLUE
NOTE
NOTE
Q4 25
Q3 25
-212.1%
-110.8%
Q2 25
-53.0%
-57.0%
Q1 25
55.2%
-15.4%
Q4 24
22.2%
Q3 24
-50.7%
Q2 24
-43.6%
Q1 24
157.6%
EPS (diluted)
GLUE
GLUE
NOTE
NOTE
Q4 25
$-2.81
Q3 25
$-1.73
Q2 25
$-0.08
Q1 25
$-0.03
Q4 24
$1.88
Q3 24
$-1.33
Q2 24
$-0.09
Q1 24
$0.37

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GLUE
GLUE
NOTE
NOTE
Cash + ST InvestmentsLiquidity on hand
$208.3M
$26.3M
Total DebtLower is stronger
$128.4M
Stockholders' EquityBook value
$245.8M
$62.0M
Total Assets
$459.8M
$255.1M
Debt / EquityLower = less leverage
2.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GLUE
GLUE
NOTE
NOTE
Q4 25
$26.3M
Q3 25
$208.3M
$31.2M
Q2 25
$69.4M
$38.5M
Q1 25
$78.5M
$46.3M
Q4 24
$224.3M
$34.6M
Q3 24
$32.7M
Q2 24
$37.7M
Q1 24
$43.6M
Total Debt
GLUE
GLUE
NOTE
NOTE
Q4 25
$128.4M
Q3 25
$131.5M
Q2 25
$116.7M
Q1 25
$118.0M
Q4 24
$147.1M
Q3 24
$152.2M
Q2 24
$145.9M
Q1 24
$153.0M
Stockholders' Equity
GLUE
GLUE
NOTE
NOTE
Q4 25
$62.0M
Q3 25
$245.8M
$75.5M
Q2 25
$268.1M
$95.1M
Q1 25
$275.2M
$98.7M
Q4 24
$222.9M
$97.8M
Q3 24
$98.5M
Q2 24
$106.9M
Q1 24
$106.1M
Total Assets
GLUE
GLUE
NOTE
NOTE
Q4 25
$255.1M
Q3 25
$459.8M
$273.9M
Q2 25
$359.6M
$288.3M
Q1 25
$393.2M
$299.7M
Q4 24
$438.7M
$326.2M
Q3 24
$337.9M
Q2 24
$346.3M
Q1 24
$357.8M
Debt / Equity
GLUE
GLUE
NOTE
NOTE
Q4 25
2.07×
Q3 25
1.74×
Q2 25
1.23×
Q1 25
1.20×
Q4 24
1.50×
Q3 24
1.54×
Q2 24
1.36×
Q1 24
1.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GLUE
GLUE
NOTE
NOTE
Operating Cash FlowLast quarter
$100.4M
$-279.0K
Free Cash FlowOCF − Capex
$99.8M
$-1.9M
FCF MarginFCF / Revenue
781.5%
-8.7%
Capex IntensityCapex / Revenue
5.1%
7.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$145.0M
$-18.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GLUE
GLUE
NOTE
NOTE
Q4 25
$-279.0K
Q3 25
$100.4M
$-8.3M
Q2 25
$-34.7M
$-6.2M
Q1 25
$-45.5M
$3.3M
Q4 24
$128.9M
$-1.3M
Q3 24
$-3.0M
Q2 24
$-3.7M
Q1 24
$2.7M
Free Cash Flow
GLUE
GLUE
NOTE
NOTE
Q4 25
$-1.9M
Q3 25
$99.8M
$-10.4M
Q2 25
$-36.4M
$-7.7M
Q1 25
$-47.1M
$1.3M
Q4 24
$128.7M
$-3.4M
Q3 24
$-5.4M
Q2 24
$-6.5M
Q1 24
$1.0M
FCF Margin
GLUE
GLUE
NOTE
NOTE
Q4 25
-8.7%
Q3 25
781.5%
-46.2%
Q2 25
-157.0%
-33.0%
Q1 25
-55.4%
4.7%
Q4 24
212.3%
-11.4%
Q3 24
-18.4%
Q2 24
-22.1%
Q1 24
3.3%
Capex Intensity
GLUE
GLUE
NOTE
NOTE
Q4 25
7.4%
Q3 25
5.1%
9.3%
Q2 25
7.3%
6.4%
Q1 25
1.9%
7.2%
Q4 24
0.3%
6.8%
Q3 24
8.3%
Q2 24
9.4%
Q1 24
5.3%
Cash Conversion
GLUE
GLUE
NOTE
NOTE
Q4 25
Q3 25
Q2 25
Q1 25
-0.97×
Q4 24
9.59×
Q3 24
Q2 24
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GLUE
GLUE

Segment breakdown not available.

NOTE
NOTE

Subscription$21.2M95%
Advisory Advertising And Other$1.0M5%

Related Comparisons